pharmaphorum

JANUARY 21, 2022

Research led by UCLH, UCL and the Francis Crick Institute found that the booster dose successfully stimulates antibody levels that neutralise Omicron. Overall, antibody levels were nearly 2.5 Details of the study were published in The Lancet this week. times higher against Omicron after three doses compared to after two.”.

Antibody 115

Antibody Vaccination Vaccine Genotype 115

Pharmaceutical Technology

MAY 22, 2023

SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders. It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s).

Immune Response 273

Immune Response Clinical Trials Clinical Trials Antibody 273

XTalks

JULY 25, 2022

Later lines of treatment can include monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates (ADCs). XTALKS WEBINAR: Discussing the Concerns within Clinical Research in Oncology and In-Home Healthcare. ADCs consist of an antibody attached to a cytotoxin that is delivered to targeted cells.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

The Pharma Data

NOVEMBER 22, 2020

FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies with Pandion Therapeutics (Pandion). We now have a pipeline of undisclosed therapeutic partnerships nearing clinical research.

Antibody 52

Antibody Immune Response Engineer Protein 52

XTalks

DECEMBER 28, 2023

BillionToOne, a company specializing in molecular diagnostics, has partnered with Janssen Research & Development, LLC, a Johnson & Johnson division, to conduct the AZALEA Phase III clinical trial globally. Nipocalimab is an investigational monoclonal antibody that targets the neonatal Fc receptor.

Trials 97

Trials Clinical Trials Clinical Trials Antibody 97

XTalks

JANUARY 17, 2024

Estimates based on publicly available information suggest more than 40 percent of all new therapies in development are cancer treatments. There are many aspects of oncology drug development that are driven by the unique nature of the treatments being developed and the needs of the patients, their caregivers and the doctors that treat them.

Clinical Trials 124

Clinical Trials Clinical Trials Trials Gene Therapy 124

BioPharma Reporter

OCTOBER 27, 2020

The clinical research solutions firm is joining forces with pharma giant Eli Lilly to manage mobile research of the monoclonal antibody LY-CoV555.

Research 98

Research Antibody Clinical Research Trials 98

Drug Discovery World

OCTOBER 17, 2023

The free two-hour Summit ‘Cancer research opportunities and advances’, hosted by DDW, will take place online on 16 November at 7AM PDT / 10AM EDT / 3PM GMT / 4PM CET. The presentation will address important issues in antibody drug development, including choosing the right biomarker, drug formulation and manufacturing.

Research 52

Research Marketing Antibody Clinical Trials 52

pharmaphorum

OCTOBER 21, 2022

The acquisition of DJS Antibodies, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins – such as G protein-coupled receptors (GPCRs) – will extend AbbVie’s present discovery research capabilities, through DJS’ proprietary HEPTAD platform.

Antibody 59

Antibody Protein Research Medicine 59

Delveinsight

NOVEMBER 26, 2020

Genmab discards antibody-drug conjugate after the early-phase fiasco. Genmab is ditching an antibody-drug conjugate after it flunked the mark in early-phase trials. The rest of the funds would bankroll the development of tisotumab vedotin and take it to the market, and drive other programs through the clinic. Clancy, M.D.,

Antibody 79

Antibody Trials Drugs Engineer 79

XTalks

MARCH 20, 2024

When it comes to leadership in clinical trials today, what qualities are necessary to navigate the evolving landscape of clinical research effectively? Xtalks recently had the opportunity to discuss Enciso’s journey in the clinical research industry and her decision to join Regeneron.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

Drug Discovery World

OCTOBER 20, 2022

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research. . Developing and securing human resources with digital skills.

Development 52

Development Drugs Life Science Marketing 52

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Oral therapy data presented at ASH. CellCentric, a U.K-based Professional reception of the findings.

Development 52

Development Drugs Clinical Development Antibody 52

Rethinking Clinical Trials

JANUARY 17, 2024

Any patient admitted to the hospital with COVID-19 completed a COVID intake form in their admission record, and if they opted to learn about experimental therapies, a FaceTime call was set up with a research coordinator. The first monoclonal antibody (mABs) treatment for treatment of COVID-19 was approved in November 2020.

Clinical Trials 169

Clinical Trials Clinical Trials Antibody Trials 169

Find Me Cure

OCTOBER 13, 2019

If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. This Breast Cancer Awareness Month we’d like to talk about emerging areas in metastatic breast cancer treatment since clinical research has come so far in recent years.

Development 52

Development DNA Clinical Trials Clinical Trials 52

pharmaphorum

SEPTEMBER 15, 2020

Humanigen is hoping for emergency use authorisation in the US for an antibody to treat severe COVID-19 before the end of 2020, and has teamed up with Swiss contract manufacturer Lonza to make sure it can meet demand. Lilly also has studies on the go for LY3127804, an investigational antibody targeting angiopoietin 2 (Ang2).

Drugs 97

Drugs Antibody Contract Manufacturing Manufacturing 97

pharmaphorum

SEPTEMBER 29, 2020

The FDA has fast tracked development of AbbVie’s potential spinal injury drug, elezanumab, a process that will be aided by digital analysis. The regulator has also granted it orphan status, which cuts development costs and potentially boosts profits if approved. million.

Drugs 105

Drugs Development Antibody Regulation 105

XTalks

JULY 14, 2022

Uncontrolled gout is defined as gout that is unmanageable and/or develops resistance to conventional therapies. Over time, even the use of Krystexxa can lead to the development of antibodies against it, reducing its effectiveness. Early data also showed that methotrexate could prevent the formation of anti-drug antibodies.

FDA Approval 105

FDA Approval Antibody Trials Drugs 105

pharmaphorum

APRIL 7, 2021

Genmab’s success has been founded on Darzalex (daratumumab), the blockbuster multiple myeloma drug that it developed in partnership with Johnson & Johnson’s Janssen unit. With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies.

Antibody 84

Antibody Life Science Development Regulation 84

Drug Discovery World

MARCH 24, 2023

This week we have seen a number of developments in the treatment of solid tumours hitting the headlines. Pennsylvania researchers may have found a way to boost CAR-T therapy in these tumours, previously only successful in blood cancers, which could have huge implications for cancer treatment.

Drugs 52

Drugs Hormones Trials Research 52

pharmaphorum

JULY 7, 2022

In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it saved precious time in the work to develop a working vaccine during the current pandemic. Building blocks.

Vaccination 104

Vaccination Vaccine Development Research 104

Drug Discovery World

MARCH 10, 2023

Research organisations partner to transform clinical trials The Duke Clinical Research Institute (DCRI) and Protas, led by Oxford University clinical trialist Professor Sir Martin Landray, will collaborate to develop new approaches to large randomised clinical trials.

In-Vivo 52

In-Vivo Clinical Trials Clinical Trials Drugs 52

Drug Discovery World

FEBRUARY 12, 2024

Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery. The emergence of low-code and no-code software engineering will start to make CGT application development easier, enabling more rapid, innovative solutions.

Genome 139

Genome Genomics Life Science Gene Therapy 139

Drug Discovery World

APRIL 15, 2023

BDC-3042 is an agonistic antibody targeting Dectin-2, an immune-activating receptor expressed by TAMs. Tumour-associated macrophages (TAMs) are an abundant immune cell population in many solid tumours and play a key role in establishing the immunosuppressive tumour microenvironment that enables tumour progression.

Antibody 52

Antibody Trials Research Gene Editing 52

Roots Analysis

MARCH 16, 2022

Presently, outsourcing of exosome related services has become a popular practice where drug developers are actively outsourcing their operations to specialized repurposed-based service providers, which are known to have the required capabilities and expertise. Broad Clinical Trial Landscape. Want additional details on the pipeline?

Marketing 59

Marketing Manufacturing Drug Delivery Drug Delivery Systems 59

Advarra

MARCH 10, 2023

Having a one in four chance of developing sickle cell disease (SCD) is uniquely, and overwhelmingly, familiar to the African American population. Considered a rare disease, research in finding better therapies – and possibly even a cure – for SCD may be competing for funding with conditions impacting broader populations.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Doctors 98

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

The Pharma Data

NOVEMBER 1, 2020

This clinical trial will be coordinated by the team at the INTRIALS, a leading, full-service Latin America Clinical Research Organization (CRO), based in Sao Paulo City, Brazil. The clinical data from this trial is expected to available by the end of this year. Brazil has reported almost 5.5M About Tiziana Life Sciences.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Life Science 52

pharmaphorum

JULY 20, 2021

Gilead Sciences just forged even closer ties with its cancer drug partner Arcus Biosciences, enticing the biotech’s chief medical officer Bill Grossman to a new role as its head of oncology clinical research. billion last year to claim ownership of magrolimab, a CD47-targeting antibody in trials for blood cancers.

Antibody 52

Antibody Clinical Research Drugs Clinical Development 52

pharmaphorum

DECEMBER 12, 2022

The San Antonio Breast Cancer Symposium (SABCS) has highlighted some of the most promising clinical research being undertaken by drugmakers in the category, with AstraZeneca leading the charge with a trio of major trial readouts. after four years’ follow-up, an improvement on the 2.8% seen at two years.

HR 105

HR Hormones Trials Drugs 105

Roots Analysis

MARCH 6, 2022

These proteins interact with multiple immune cells and complement the action of antibodies, which are in turn responsible for killing the infectious agents. Complement Therapeutics: The Clinical Antidote for Complement-Associated Diseases. The main focus is to develop innovative therapies with reduced cost and increased safety.

Regulation 52

Regulation Protein Antibody Marketing 52

Pharmaceutical Technology

JANUARY 30, 2023

Numerous drug approval applications to the FDA failed in 2022, including oncology monoclonal antibodies (mAbs) such as Eli Lilly and Co’s (Indianapolis, IN, US) sintilimab, Y-mAbs Therapeutics Inc’s (New York, NY, US) omburtamab, and Coherus BioSciences’ (Redwood City, CA, US) toripalimab.

Drugs 130

Drugs Manufacturing Contract Manufacturing FDA Approval 130

pharmaphorum

AUGUST 5, 2020

Now US-based Merck wants to see if it can get Hanmi’s drug, known as efinopegdutide, to work in NASH after J&J walked away from developing it in obesity. As well as the up front $10 million payment, South Korea’s Hanmi could receive milestone payments up to $860 million if certain development, regulatory and commercial targets are met.

Drugs 52

Drugs Clinical Trials Clinical Trials Marketing 52

Roots Analysis

AUGUST 14, 2023

Antibodies are key components of the immune system that bind to specific markers on cells or tissues, thereby offering first line of defense against multiple disorders. The novel antibody therapies include different classes of antibodies, that are responsible for killing or inhibiting disease-causing agents.

Antibody 52

Antibody Development Marketing Engineer 52

The Pharma Data

NOVEMBER 16, 2020

The mRNA-1273 vaccine candidate was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna, Inc., It combines Moderna’s mRNA (messenger RNA) delivery platform with the stabilized SARS-CoV-2 spike immunogen (S-2P) developed by NIAID scientists. El Sahly, M.D., Baden, M.D.,

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial.

Protein 126

Protein Vaccination Vaccine Immune Response 126

Roots Analysis

MARCH 24, 2022

However, research related to metabolites is essential to increase the understanding of molecular level interactions, functions, modifications and regulations in cells, therefore, the field of metabolomics plays a vital role in biomarker discovery for early disease diagnosis and prognosis as well as for drug discovery and development processes.

Clinical Research 52

Clinical Research Development Research Drug Delivery Systems 52